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ost of the effects of the signaling molecule nitric
oxide (NO) are mediated by cGMP, which is
synthesized by soluble guanylyl cyclase and
degraded by phosphodiesterases. Here we show that in
platelets and aortic tissue, NO led to a biphasic response
characterized by a tremendous increase in cGMP (up to
100-fold) in less than 30 s and a rapid decline, reﬂecting
the tightly controlled balance of guanylyl cyclase and
phosphodiesterase activities. Inverse to the reported increase
in sensitivity caused by NO shortage, concentrating NO
attenuated the cGMP response in a concentration-depen-
M
 
dent manner. We found that guanylyl cyclase remained
 
fully activated during the entire course of the cGMP response;
thus, desensitization was not due to a switched off guanylyl
cyclase. However, when intact platelets were incubated
with NO and then lysed, enhanced activity of phosphodi-
esterase type 5 was detected in the cytosol. Furthermore,
this increase in cGMP degradation is paralleled by the
phosphorylation of phosphodiesterase type 5 at Ser-92.
Thus, our data suggest that NO-induced desensitization of
the cGMP response is caused by the phosphorylation and
subsequent activity increase of phosphodiesterase type 5. 
 
Introduction
 
Nitric oxide (NO)* has been identified as an important sig-
naling molecule playing a crucial role in the cardiovascular
and nervous systems (Waldman and Murad, 1987; Moncada
et al., 1991; Garthwaite and Boulton, 1995; Ignarro et al.,
1999). Most of NO’s effects are mediated via the stimula-
tion of soluble guanylyl cyclase (sGC), which leads to en-
hanced conversion of GTP to cGMP. sGC, a heterodimer
consisting of an 
 
 
 
 and 
 
 
 
 subunit each (Koesling and Friebe,
1999), contains a prosthetic heme group that is required for
NO stimulation. The cellular effects of cGMP are mediated
by the activation of different cGMP effector proteins such as
the cGMP-dependent protein kinases (cGKs; Hofmann et
al., 2000) and the cGMP-regulated phosphodiesterases
(PDEs; Juilfs et al., 1999), and the cGMP-gated ion chan-
nels (Biel et al., 1999). The NO-induced increase in the
cGMP concentration is counteracted by the activation of
PDEs, which are responsible for the degradation of cGMP
(Francis et al., 2001).
During the last few years, several reports indicated a possible
modulatory influence of NO on the cGMP response in addi-
tion to its sGC stimulatory action. In fact, a lack of NO caused
by either endothelium removal, gene disruption, or inhibition
of the endothelial NO synthase has been reported to lead to
increased NO sensitivities in the aortic vessels; which was paral-
leled by an augmentation of NO-induced cGMP levels
(Moncada et al., 1991; Brandes et al., 2000). Decreased sensi-
tivities of the NO–cGMP system have been demonstrated un-
der various conditions after treatment with NO-releasing agents
(Waldman et al., 1986; Schroder et al., 1988; Ujiie et al., 1994;
Filippov et al., 1997). In a recent report, Bellamy et al. (2000)
showed a rapid desensitization of sGC within seconds.
 
Address correspondence to Doris Koesling, Abteilung für Pharmakologie
und Toxikologie, Medizinische Fakultät, Ruhr-Universität Bochum, Uni-
versitätssr. 150, D-44780 Bochum, Germany. Tel.: 49-234-3226827.
Fax: 49-234-3214521. E-mail: doris.koesling@ruhr-uni-bochum.de
*Abbreviations used in this paper: cGKI, cGMP-dependent protein ki-
nases type I; EHNA, erythro-9-(2-hydroxy-3-nonyl)-adenine; GSNO,
 
S
 
-nitrosoglutathione; NO, nitric oxide; PDE, phosphodiesterase; RIA,
radioimmunoassay; sGC, soluble guanylyl cyclase; VASP, vasodilator-
stimulated phosphoprotein.
Key words: phosphodiesterase; cGMP; NO-sensitive guanylyl cyclase;
platelets; desensitization 
272 The Journal of Cell Biology 
 
|
 
 
 
Volume 155, Number 2, 2001
 
It was the aim of the present study to investigate the short-
term NO-dependent desensitization of the cGMP response. As
the properties of the NO–cGMP system in cultured cells
change very rapidly during cell cultivation (Wyatt et al., 1998;
unpublished data), we chose platelets and aortic smooth mus-
cle as model systems. Here, we show that short-term preincu-
bation of human platelets and rat aortic strips with submaxi-
mally activating 
 
S
 
-nitrosoglutathione (GSNO) concentrations
blunted the NO-induced cGMP response. In contrast to a re-
cent report (Bellamy et al., 2000), the decrease in the cGMP
response was not based on sGC desensitization, as in our ex-
periments the enzyme remained fully activated. Our data show
that within a few seconds of the NO incubation of intact plate-
lets, an increase in PDE5 activity can be detected in the cytoso-
lic fractions; a result that is paralleled by an increase in phos-
phorylation of PDE5 at Ser-92. Therefore, we postulate that
activation of PDE5, not desensitization of sGC, is responsible
for the NO-induced desensitization of the cGMP response.
 
Results
 
One of the important functions of NO in the cardiovascular
system is the inhibition of platelet aggregation. In these cells,
NO stimulation of sGC and the resulting cGMP increase
leads to the activation of the cGMP-dependent protein ki-
nase type I (cGKI), which subsequently phosphorylates
several substrate proteins including vasodilator-stimulated
phosphoprotein (VASP). The rapid GSNO-induced cGMP
response in human platelets is shown in Fig. 1 A. This bi-
phasic response is characterized by a fast increase in cGMP
reaching a maximum after 5–10 s, and a subsequent decrease
leading to a plateau close to basal levels after 40–60 s. At the
highest concentration, GSNO elicited a 30-fold increase in
intraplatelet cGMP levels compared with basal level (300 
 
 
 
40 and 10 
 
 
 
 3 pmol/10
 
9
 
 platelets, respectively). As ex-
pected, at lower GSNO concentrations, peak cGMP levels
reached after 5–10 s were reduced, even though the biphasic
profile of the cGMP response remained identical.
To assess the physiological relevance of the rapid increase
in the intracellular cGMP concentration, the activity of the
downstream cGMP effector, cGKI, was studied in human
platelets. Activity of cGKI was determined by monitoring
the phosphorylation of VASP, a well-characterized substrate
of cGKI (Smolenski et al., 1998). As shown in Fig. 1 B, a
marked immunoreactive signal with the appropriate molec-
ular mass of 46 kD was detected as soon as 3 s after addition
of GSNO, indicating a rapid transduction of the cGMP sig-
nal to cGKI and further onto VASP. The observed shift of
the protein band from the apparent mass of 46 to 50 kD was
caused by further phosphorylation of VASP at a second resi-
due (Smolenski et al., 1998).
Next, to investigate the possible modulation of the cGMP
response by NO, we performed preincubation experiments.
First, we applied submaximally effective GSNO concentra-
tions (3, 10, and 30 
 
 
 
M) for 3 min (Fig. 2), a period after
which the intraplatelet cGMP levels had declined to almost
basal levels (Fig. 1 A). After this 3-min preincubation, plate-
lets were stimulated with the maximally effective concentra-
tion of GSNO (300 
 
 
 
M; Fig. 1), and cGMP levels were de-
termined over time. As expected, under control conditions
(0 
 
 
 
M GSNO during preincubation), the cGMP response
to 300 
 
 
 
M GSNO resembled that seen in Fig. 1. However,
GSNO preincubation attenuated the cGMP responses in a
concentration-dependent manner, when induced by maxi-
Figure 1. Time course of cGMP levels and VASP phosphorylation 
in human platelets after stimulation with GSNO. (A) Washed 
human platelets were stimulated with increasing concentrations of 
GSNO. After stopping the reaction at the indicated time points, 
cGMP was extracted and measured by RIA. Shown is a representative 
experiment out of a total of five experiments performed in dupli-
cates. (B) After stimulation with 300  M GSNO for the time indi-
cated, platelets were lysed and cytosolic proteins were separated by 
SDS-PAGE and blotted. VASP phosphorylation was detected with a 
phosphospecific monoclonal antibody. The shift of the protein band 
from the apparent mass of 46 to 50 kD was caused by further phos-
phorylation of VASP at a second residue. Shown is a representative 
experiment out of three performed with similar results.
Figure 2. NO-induced desensitization of the cGMP response in 
human platelets. Platelets preincubated for 3 min with the indicated 
concentrations of GSNO were stimulated with a maximally effective 
GSNO concentration (300  M; indicated by the arrow). cGMP 
accumulation at the indicated time points was determined by RIA. 
Shown is a representative experiment out of a total of three 
experiments performed in duplicates. 
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mally effective GSNO. The use of 30 
 
 
 
M GSNO during
preincubation almost totally abrogated the NO-induced
cGMP response in platelets. These data indicate a rapidly in-
duced desensitization of the cGMP response. Furthermore,
the degree of NO sensitivity of the cGMP system appears to
be inversely related to the amount of NO present during
preincubation of the platelets.
To see whether the observed NO-induced decrease in the
cGMP response was a special feature of platelets, we chose
rat aortic strips as another system; here, the cGMP system is
known to play an important role in the regulation of smooth
muscle tone. To prevent endogenously produced NO from
affecting the sensitivity state of the cGMP system, the exper-
iments with aortic strips were performed in the presence of
the NO synthase inhibitor 
 
N
 
-nitro-
 
L
 
-arginine methyl ester
(200 
 
 
 
M). Application of GSNO (300 
 
 
 
M) led to a bipha-
sic cGMP response similar to that seen in human platelets
(Fig. 3 A), consisting of a fast and enormous increase in
cGMP levels (150-fold; maximum after 20–30 s) followed
by a rapid and pronounced decrease. Although the amount
of cGMP measured in the aortic preparations from different
animals varied considerably (0.5–1.5 and 100–250 pmol/
mg protein under basal and stimulated conditions, respec-
tively), the biphasic shapes of the responses were qualita-
tively similar.
Next, we tested whether NO-induced desensitization of
the cGMP system also occurred in aortic tissue, using a sim-
ilar experimental setup as described for the platelets in Fig.
2. Aortic strips were preincubated for 3 min with submaxi-
mally effective GSNO concentrations and then stimulated
with 300 
 
 
 
M GSNO. cGMP levels were determined at one
single time point, i.e., 30 s after NO stimulation (Fig. 3 B).
Preincubation with NO attenuated the NO-induced cGMP
Figure 3. Time course of NO-induced cGMP levels and NO-induced 
desensitization of the cGMP response in rat aortic strips. (A) Aortic 
strips were stimulated with 300  M GSNO for the times indicated. 
After shock freezing and homogenization of the tissue, the extracted 
cGMP was measured by RIA. As the amount of cGMP measured in 
the aortic preparations from different animals varied considerably, 
data are expressed as the percentage of maximal stimulation. 
(B) Aortic strips preincubated for 3 min with the indicated concen-
trations of GSNO were stimulated with 300  M GSNO, and cGMP 
levels were measured after 30 s. Data represent means   SEM of 
nine independent experiments performed in duplicates (A) or
means   SEM of triplicate determinations in one representative
experiment out of a total of three similar experiments (B).
Figure 4. Time course of NO-induced cGMP accumulation in 
human platelets in the presence of PDE inhibitors. (A) Platelets 
preincubated for 20 min with inhibitors specific for PDE5 and 
PDE2, sildenafil and EHNA, respectively, (100  M each; filled 
circles) were stimulated with 300  M GSNO. Then, platelets were 
lysed at the indicated time points, and cGMP was determined by 
RIA. For comparison, the cGMP response in the absence of PDE 
inhibitors is shown (open circles). (B) Platelets were preincubated 
for 20 min with sildenafil and EHNA (100  M each). After 17 min, 
GSNO was added at the indicated concentrations (i.e., 3-min pre-
incubation). At time point zero, a maximally effective GSNO con-
centration (300  M; indicated by the arrow) was administered. 
Platelets were lysed at the indicated time points, and cGMP 
accumulation was determined by RIA. For comparison, cGMP 
accumulation without NO preincubation is also shown (filled 
circles with dotted line). Data represent means   SEM from three 
independent experiments performed in duplicates. 
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response in a concentration-dependent manner. As seen in
platelets, these data show the desensitizing effect of NO on
the cGMP response in vascular smooth muscle.
Our next experiment investigated the underlying mecha-
nism of the observed desensitization in the platelets. Intra-
cellular cGMP levels reflect the state of activity of the
cGMP-forming sGC and cGMP-degrading PDEs. There-
fore, decreased synthesis or enhanced degradation should ac-
count for the desensitization of the cGMP response. To find
out whether desensitization occurred on the level of sGC,
NO-induced cGMP formation was determined in the pres-
ence of PDE inhibitors. As PDE5 and PDE2 are the major
enzymes responsible for cGMP degradation in platelets, we
chose the respective, specific inhibitors sildenafil and
erythro-9-(2-hydroxy-3-nonyl)-adenine (EHNA). Under a
blockade of the two PDEs, cGMP levels did not decrease af-
ter the initial rise in cGMP but rather came to an enor-
mously elevated plateau within 60–120 s (Fig. 4 A). On this
plateau, cGMP levels were 
 
 
 
10-fold higher than the maxi-
mal levels seen in the absence of PDE inhibitors (3,000 vs.
300 pmol/10
 
9
 
 platelets; Fig. 4 A). Fig. 4 B shows NO prein-
cubation experiments in the presence of PDE inhibitors per-
formed similar to those in Fig. 2. GSNO preincubation (3,
10, and 30 
 
 
 
M for 3 min) in the presence of PDE inhibitors
led to augmented cGMP levels at time point zero, since the
cGMP formed during preincubation was not degraded. Al-
though the initial rate of cGMP formation in the control
sample appeared greater than the rates of the NO-preincu-
bated samples, cGMP levels reached a similar plateau in all
cases. Calculation revealed an extremely high concentration,
 
 
 
600 
 
 
 
M, of intraplatelet cGMP (see Discussion). There-
fore, reduction of the substrate GTP concentration could
not be ruled out.
To find out whether NO-induced cGMP formation in
the presence of PDE inhibitors leads to a significant reduc-
tion of the substrate GTP, we measured intraplatelet GTP
concentrations using HPLC. Original traces of the GTP
peaks of NO-stimulated platelets in the absence (control;
dotted line) and presence of both PDE inhibitors (100 
 
 
 
M
each; solid line) are shown in Fig. 5 A. Clearly, the inhibi-
tion of PDEs in NO-stimulated platelets led to a 50% re-
duction of the intracellular GTP concentration, as shown in
the statistical analysis in Fig. 5 B. Because of this massive
loss of available GTP in the stimulated platelets in the pres-
ence of PDE inhibitors, kinetic analysis of cGMP synthesis
is not appropriate.
Under substrate-depleting conditions, the actual activity
of sGC cannot be determined. Therefore, we tried to bypass
this problem by choosing a different experimental approach
that would not generate extraordinarily elevated cGMP lev-
els. Platelets were stimulated with GSNO and PDE inhibi-
tors were added at different stages of the cGMP response, as
indicated in the inset of Fig. 6 (simultaneous to NO, 0 s;
near maximum, 15 s; within the cGMP reduction phase, 30
s; and during plateau phase, 60 s). After addition of PDE in-
hibitors, aliquots of the platelet suspensions were taken every
3 s (series 1: 0, 3, 6 s; series 2: 18, 21, 24 s; series 3: 33, 36,
39 s; series 4: 63, 66, 69 s after NO stimulation), and cGMP
accumulation was measured. The increases in cGMP mea-
sured in the four series are shown in Fig. 6. Because of the
short-term application of PDE inhibitors, depletion of sub-
strate did not occur, and cGMP synthesis, i.e., sGC activity,
was unmasked within the cGMP response. Within this time
range cGMP increased linearly, and in the different series,
the rates of cGMP synthesis were similar (series 1: 109 
 
 
 
23, series 2: 102 
 
 
 
 7, series 3: 108 
 
 
 
 6, series 4: 110 
 
 
 
 20
pmol cGMP 
 
 
 
 s
 
 
 
1
 
/10
 
9
 
 platelets), indicating that the appar-
ent NO-stimulated sGC activities were similar, regardless of
the stage of the cGMP response. We conclude that sGC is
not responsible for desensitizing the cGMP response.
The rapid desensitization of the cGMP response (Fig. 2)
appears not to be based on a decrease in cGMP synthesis,
which leaves cGMP degradation as the mechanism most
likely to account for this phenomenon. Therefore, we fo-
cused on a possible modulation of PDE activity. At the dif-
ferent stages of the NO-stimulated cGMP response (0, 15,
30, and 60 s; Fig. 6, inset), platelets were lysed by sonifica-
tion, and PDE activity was then determined in the cytosolic
fraction. As shown in Fig. 7 A, cGMP degradation measured
in the presence of 1 
 
 
 
M cGMP showed 1.6-, 2.1-, and 2.4-
fold increases in enzyme activity after 15, 30, and 60 s of
NO stimulation of intact platelets, respectively. Thus, acti-
vation of PDE began simultaneously with NO exposure in
intact cells. A changed activity due to translocation of PDEs
can be ruled out, as PDE activity in the cytosol was 
 
 
 
95%
of that in the homogenate samples and was not altered by
NO stimulation (control: 94% 
 
 
 
 12%; NO-stimulated:
96% 
 
  
 
12%). To confirm that sGC does not desensitize
Figure 5. HPLC analysis of intraplatelet 
GTP levels under NO-stimulated 
conditions in the absence and presence 
of PDE inhibitors. After preincubation 
for 10 min with DMSO (control) or the 
combination of sildenafil and EHNA 
(100  M each), platelets were stimu-
lated with 300  M GSNO for 60 s. 
Subsequently, reactions were stopped 
by the addition of HClO4 (final concen-
tration 0.7 M). After precipitation of 
proteins and adjustment of the pH, nu-
cleotides were separated on a Mono-Q 
column as described under Materials 
and methods. (A) Original trace data 
shows elution of GTP at 13.3% buffer B (see Materials and methods). (B) Bars show the 
quantitative analysis as means   SEM from four independent experiments. 
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under these conditions, NO-stimulated cGMP formation
was measured in cytosolic fractions. As shown in Fig. 7 B ,
sGC activity remained unchanged.
To identify the isoform of PDE responsible for the en-
hanced degradation, cGMP breakdown was measured in the
presence of PDE inhibitors specific for PDE2 (EHNA),
PDE3 (milrinone), and PDE5 (sildenafil). Fig. 7 C shows
that cytosolic cGMP degradation was inhibited in a concen-
tration-dependent manner by sildenafil (IC
 
50
 
 of 
 
 
 
3 nM),
whereas EHNA and milrinone only prevented cGMP break-
down at very high concentrations, at which an effect on
PDE5 cannot be ruled out. Even at higher cGMP concen-
trations (10 and 100 
 
 
 
M), sildenafil inhibited the majority
of PDE activity (Fig. 7 D), whereas the addition of EHNA
(20 
 
 
 
M) caused only up to 10% inhibition of PDE activity.
The increase in PDE activity after NO incubation was still
detectable under PDE2-inhibiting conditions but almost ab-
rogated under PDE5 inhibition. Therefore, the increase in
PDE activity can be attributed to PDE5.
The fact that enhanced PDE activity was evident after
breaking up the cells suggested a covalent modification as
the mechanism underlying desensitization. Phosphorylation
of PDE5 at Ser-92 has been shown to be associated with an
increase in enzyme activity (Wyatt et al., 1998; Corbin et al.,
2000). Therefore, we studied this possible phosphorylation
by using a novel phospho-specific antibody against PDE5,
Figure 6. sGC does not desensitize during the time course of the 
NO-stimulated cGMP response in human platelets. Platelets were 
stimulated with 300  M GSNO at time point zero. PDE inhibitors 
sildenafil and EHNA (100  M each) were administered at the time 
points indicated by the arrows in the inset corresponding to different 
states of the cGMP response (see text). After addition of PDE inhibi-
tors, aliquots of the platelet suspension were removed into ice cold 
ethanol every 3 s. Extracted cGMP was then determined by RIA. For 
the very first data point at 0 s, basal cGMP levels were subtracted; 
for better comparison, the cGMP levels 3 s after addition of PDE 
inhibitors (i.e., 18, 33 or 63 s) were subtracted from the following 
cGMP levels. Thus, the y axis shows the increase in cGMP values 
within every 3 s. Values represent means   SEM of hexaplicate 
determinations in one representative experiment out of three 
similar experiments.
Figure 7. Cytosolic PDE and sGC activities after NO incubation of 
intact platelets. Platelets were stimulated with 300  M GSNO 
and lysed after 15, 30, or 60 s. (A) PDE (1  M cGMP as substrate) 
and (B) NO-stimulated sGC activities were determined in the 
supernatant fraction as described in Materials and methods. 
Values represent means   SEM of quadruplicate determinations 
in one representative experiment out of three similar experi-
ments. (C) PDE activities in the cytosol of control platelets (open 
symbols) and NO-incubated platelets (60 s; closed symbols) 
were measured in the presence of isoform-specific inhibitors 
(sildenafil, circles; EHNA, squares; milrinone, triangles). The 
activities were normalized relative to that of the control cytosol 
(no NO incubation, absence of sildenafil). Data represent
means   SEM of two independent experiments performed in
duplicates. (D) Cytosolic PDE activities were measured with 1, 
10, and 100  M cGMP in the presence of the indicated inhibi-
tors (20  M EHNA, 1  M sildenafil). The activities were normal-
ized relative to that of the control cytosol (no NO incubation,
1  M cGMP). Data represent means   SEM of two independent 
experiments performed in duplicates. 
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raised against the phosphorylated Ser-92–containing pep-
tide. Fig. 8 A shows that the antibody only reacts with the
phosphorylated and not with the unphosphorylated form of
PDE5. Platelets were stimulated with GSNO, and at the dif-
ferent stages of the NO-stimulated cGMP response (Fig. 6,
inset) aliquots of the platelet suspension were subjected to
SDS-PAGE and blotted onto nitrocellulose (Fig. 8 B). Un-
der nonstimulated conditions, PDE5 was not recognized.
Immunoreactive signals appeared already 15 s after NO
stimulation and paralleled the increased enzyme activity
within a time range of 60 s (Fig. 7 A). Phosphorylation of
PDE5 was detected with concentrations of GSNO as low as
3 
 
 
 
M (unpublished data). Thus, our data show, for the first
time, the concomitant phosphorylation and activity increase
of PDE5 over the course of the NO-stimulated cGMP re-
sponse. In conclusion, phosphorylation of PDE5 by a yet
unidentified kinase appears to be responsible for the NO-
induced desensitization of the cGMP response.
 
Discussion
 
In this article, we show that NO not only induces a rapid
cGMP response in platelets and in aortic strips but also
serves to alter the responsiveness of the cGMP cascade. In
both models, the NO-induced cGMP response is biphasic
and characterized by a very fast increase in cGMP, which
amounts to a calculated peak concentration of 
 
 
 
60 
 
 
 
M in
platelets (see below). Subsequently, the concentration of
cGMP declines rapidly, and it can be assumed that PDE ac-
tivity has outcompeted cGMP synthesis. Thus, the biphasic
cGMP accumulation profiles are indicative of a complex,
thus far poorly understood interplay of cGMP-forming and
-degrading activities.
The rapid desensitizing effect of NO is demonstrated by
preincubating platelets or aortic strips, which reveals that the
extent of the cGMP response is inversely related to the
amount of NO present during the preincubation (Figs. 2 and
3 B). At high NO concentrations, the cGMP system becomes
desensitized almost completely, whereas at low tissue concen-
trations of NO, the system retains a higher sensitivity state.
Physiologically, modulation of the sensitivity of the cGMP
response reflects the ability of the NO–cGMP system to
adapt to acute changes in NO exposition. Thus, information
is not only transduced within the NO–cGMP system but is
also processed for adaptation to the amount of NO available.
The reduced sensitivity of the cGMP response after NO
preincubation can be explained by either reduced cGMP
synthesis and/or enhanced cGMP degradation. To solely
monitor cGMP formation (i.e., the actual sGC activity),
PDE inhibitors can be used to prevent GMP breakdown.
Based mainly on this approach, i.e., measurements of cGMP
accumulation in the presence of PDE inhibitors, a recent re-
port suggested a rapid NO-induced desensitization of plate-
let sGC (Bellamy et al., 2000).
These results and our data (Fig. 4 A, inset) are in perfect
accordance with the 10-fold elevation of NO-induced
cGMP levels caused by the addition of PDE inhibitors
(3,000 pmol/10
 
9
 
 platelets equaling 1,500 pmol/mg pro-
tein, assuming a protein content of 2 mg/10
 
9
 
 platelets;
Eigenthaler et al., 1992). The plateau of the cGMP re-
sponse, reached after 60 s in the presence of PDE inhibi-
tors, indicates low cGMP-forming activity, which could be
attributed to a switched-off sGC. Peculiarly, NO-preincu-
bated platelets reached a similar plateau (Fig. 4 B) sug-
gesting that this intracellular cGMP concentration may
represent an “ultimate” level for cGMP accumulation.
However, the decrease in sGC activity could also be ex-
plained by a reduction in substrate GTP. Assuming a sin-
gle platelet volume of 5.2 fl (Corash et al., 1977), these
peak cGMP levels correspond to an intraplatelet concen-
tration of 
 
 
 
600 
 
 
 
M (intracellular GTP levels between 400
and 800 
 
 
 
M have been published; Traut, 1994). Under
normal conditions, sGC will cyclize GTP to cGMP, which
is then hydrolyzed to GMP by PDEs. GMP will be readily
phosphorylated to GDP and GTP by nucleoside mono-
and diphosphate kinases, respectively. The only enzymes
able to convert cGMP to GMP and hence back into the
GMP/GDP/GTP metabolism are the PDEs. Production of
cGMP in the presence of PDE inhibitors can be viewed as
a “dead-end” for guanosine phosphates; accordingly, we
see a dramatic accumulation of cGMP and a 50% reduc-
tion of intraplatelet GTP levels. Taking compartmentaliza-
tion as well as protein-bound GTP into account, it is very
likely that this decrease in GTP leads to a massive reduc-
tion in accessible substrate for sGC.
Figure 8. Detection of PDE5 phosphorylation. (A) Purified 
unphosphorylated and phosphorylated GST–PDE5 fusion proteins 
( 85 kD; 200 ng, each) were subjected to SDS-PAGE and trans-
ferred to nitrocellulose. Membranes were incubated with the 
antiphospho-PDE5 antibody in a dilution of 1:10,000. (B) Platelets 
were stimulated with 300  M GSNO. At the indicated time points, 
aliquots (3.6   10
7 platelets) were removed and proteins were 
separated by SDS-PAGE and transferred to nitrocellulose. Mem-
branes were incubated with phospho-PDE5–specific antibody in 
a dilution of 1:50,000. 
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Realizing that substrate depletion could account for the
reduction in cGMP forming activity, our next experiment
was designed to avoid GTP depletion, and sGC was revealed
to be fully active during the entire cGMP response. Here,
sGC activities obtained at various time points during the
NO-induced cGMP response were practically identical to
the initial velocity measured directly after NO/sildenafil/
EHNA coadministration (Fig. 6).
If sGC is not responsible, a change in PDE activity has to
account for the desensitization of the cGMP response. In fact,
we were able to show increased PDE activity in the cytosol of
NO-incubated, intact platelets, in which sGC activity re-
mained unaffected. Although the NO-induced increases in
PDE activity were modest, they may well be sufficient to
counteract cGMP synthesis. Rough calculation reveals a PDE
activity in platelet cytosol of 
 
 
 
40 pmol/s per 10
 
9
 
 platelets
at 1 
 
 
 
M cGMP (Fig. 7 A; 1 ml of cytosolic fraction contains
1.37 
 
 
 
 10
 
8
 
 platelets). NO-stimulated cGMP formation by
guanylyl cyclase ranges between 100 and 110 pmol cGMP/s
per 10
 
9
 
 platelets (Fig. 6). Thus, a 2.4-fold increase in cGMP
degradation, after 60 s (Fig. 7 A), is sufficient to increase PDE
activity to the level of sGC activity. The resulting net cGMP
accumulation of zero explains the “plateau” phase, after 30 s,
in which cGMP levels are low although guanylyl cyclase re-
mains active (Fig. 6). In combination with the NO-induced
activation, substrate-linked activation of PDE (Fig. 7 D) leads
to PDE activity exceeding that of sGC, which is required for
net cGMP reduction. The observed increase in PDE activity
can be attributed to PDE5, as shown by sildenafil inhibition.
Furthermore, the detection of enhanced PDE5 activity after
disruption of cell integrity indicates a covalent modification as
the mechanism underlying desensitization.
In fact, Wyatt et al. (1998) have shown that ANP-induced
cGMP accumulation leads to phosphorylation of PDE5 in
primary vascular smooth muscle cells concomitant with a
two- to fourfold increase in the catalytic activity of the immu-
noprecipitated enzyme. In vitro, phosphorylation of this PDE
isozyme was shown to result in a 50–70% increase in catalytic
activity (Corbin et al., 2000). Our experiments (Fig. 8) with a
novel antibody show that phosphorylation of PDE5 occurs
within the same time range as the observed increase in PDE
activity (Fig. 7 A). Furthermore, phosphorylation of PDE5
was detected in a sample with a GSNO concentration as
small as 3 
 
 
 
M. Interestingly, this was the lowest concentra-
tion that led to increased cGMP formation and desensitiza-
tion of the cGMP response (Figs. 1 A and 2). In sum, our
data suggest that phosphorylation of PDE5 is the underlying
mechanism of the NO-induced desensitization of the cGMP
response. Although it is tempting to speculate on cGKI, the
kinase responsible for PDE5 phosphorylation remains to be
identified. The presented data emphasize the complexity of
the tightly regulated concert of cGMP synthesis and degrada-
tion in the intact cell, and underline the therapeutic impor-
tance of PDEs as pharmacological targets.
 
Materials and methods
 
Time course of intraplatelet cGMP accumulation
 
Venous blood from healthy volunteers was drawn into ACD (85 mM triso-
dium citrate, 65 mM citric acid, 100 mM glucose) and platelets were pre-
pared as described previously (Friebe et al., 1998). Aliquots (900 
 
 
 
l) of the
 
platelet suspension containing 1.5 
 
  10
8 platelets/ml were equilibrated at
37 C for 10 min, followed by addition of GSNO at the indicated concen-
trations. At the indicated time points, an aliquot of the suspension corre-
sponding to 1.35   10
7 platelets was removed into ice cold ethanol (final
concentration 66%). Vials were put on ice for 30 min and centrifuged at
4 C and 20,000 g for 15 min. Supernatants were dried at 95 C and the
cGMP content was determined using a radioimmunoassay (RIA) as de-
scribed before (Friebe et al., 1998). Assays were performed in duplicates,
unless otherwise indicated.
Phosphorylation of VASP
Platelets (5   10
8/ml) were stimulated with 300  M GSNO; at the indi-
cated time points, an aliquot (4.5   10
7 platelets) was removed into Laem-
mli buffer and heated to 95 C for 5 min. Detection of VASP phosphoryla-
tion was performed as described previously (Friebe et al., 1998).
Determination of cGMP levels in intact aortic strips
Aortas from male Wistar-Kyoto rats were cleaned of connective tissue and
cut into strips of 2–5 mg wet weight. Before stimulation with GSNO, strips
were allowed to equilibrate in the presence of 200  M N-nitro-L-arginine
methyl ester for 1 h (37 C) in Krebs-Henseleit solution (118 mM NaCl, 4.7
mM KCl, 2.5 mM CaCl2, 1.2 mM KH2PO4, 1.2 mM MgSO4, 25 mM
NaHCO3, 7.5 mM glucose), pH 7.4, gassed with 95% O2 and 5% CO2. In
the case of preincubation, samples were treated with the indicated GSNO
concentrations for 3 min and then washed twice. Stimulation with the
maximally effective GSNO concentration was performed 2 min after the
second wash. To terminate the reactions, tissue was shock frozen using
metal forceps precooled in liquid nitrogen. Isolation and measurement of
cGMP was performed as described (Rothermund et al., 2000). Protein con-
tent was determined using the bicinchoninic acid method.
HPLC detection of GTP
After GSNO stimulation of platelets in the absence or presence of the PDE
inhibitors sildenafil and EHNA (100  M, respectively), the reactions were
stopped by the addition of 0.8 M HClO4. After centrifugation (15 min at
20,000 g and 4 C), supernatants were adjusted to pH 12.0 with KOH and
frozen at –80 C. After a second centrifugation step, supernatants were di-
luted into running buffer A (see below), and pH was adjusted to that of the
running buffer. Samples were loaded onto a Mono-Q HR5/5 column (Am-
ersham Pharmacia Biotech) and eluted with a linear gradient (buffer A: 20 mM
K2HPO4, pH 8.0; buffer B: 1 mM NaCl, 20 mM K2HPO4, pH 8.0; 0–20% B,
240 min; flow rate 0.5 ml/min). Elution of nucleotides was monitored at
254 nm; GTP was identified by co-chromatography of 
32P–GTP.
Determination of cGMP synthesis in platelets
NO-stimulated cGMP synthesis in platelets was assessed by adding the indi-
cated PDE inhibitors (100  M sildenafil and EHNA) either simultaneously
with GSNO or 15, 30, or 60 s after addition of GSNO. Subsequently, ali-
quots of the platelet suspension were removed every 3 s for cGMP determi-
nation. Experiments were performed in triplicates or hexaplicates.
Measurement of PDE and sGC activities in the cytosolic fraction 
of platelets
Platelet suspensions were adjusted to 3   10
8 platelets/ml. Aliquots of 450
 l were equilibrated at 37 C for 10 min and stimulated with 50  l GSNO
yielding a final concentration of 300  M. After the indicated incubation
time, 500  l of an ice cold protease inhibitor cocktail (2  M pepstatin A,
0.4  M benzamidine, 0.5 mM PMSF, 2 mM sodium vanadate, 1 mg/ml
BSA, 4 mM DTT) was added, and the suspension was briefly sonicated
(one pulse of 5 s) on ice using a Branson Sonifier B-12. After centrifugation
(15 min, 4 C, 20,000 g), PDE activity in the supernatant was measured by
the conversion of 
32P-cGMP (synthesized from [ -
32P]GTP using purified
sGC) to guanosine and 
32P-phosphate in the presence of alkaline phos-
phatase at 37 C for 10 min. Reaction mixtures contained 1  l of the super-
natants, 
32P-cGMP (10,000–50,000 cpm), 1  M cGMP, 12 mM MgCl2, 3
mM DTT, 0.5 mg/ml BSA, 1 U of alkaline phosphatase, and 50 mM trieth-
anolamine/HCl, pH 7.4, in a total volume of 0.1 ml. Reactions were
stopped by the addition of 900  l ice cold charcoal suspension (20% acti-
vated charcoal in 50 mM KH2PO4, pH 2.3). After pelleting the charcoal by
centrifugation, 
32P-phosphate was measured in the supernatant. For the de-
termination of sGC activity, 10  l of the supernatant was measured in the
presence of [ -
32P]GTP (500,000 cpm), 300  M GTP, 3 mM MgCl2, 3 mM
DTT, 1 mM cGMP, 0.5 mg/ml BSA, 300  M GSNO, 1 mM IBMX and a
GTP-regenerating system (0.025 mg creatine kinase, 5 mM creatine phos-
phate), and 50 mM triethanolamine/HCl, pH 7.4, in a total volume of 0.1
ml as described previously (Friebe et al., 1996).278 The Journal of Cell Biology | Volume 155, Number 2, 2001
Generation of antiphospho-Ser92-PDE5 antibody and GST-PDE5
Antiphospho-Ser92-PDE5 antibody was raised by immunizing rabbit with
keyhole limpet hemocyanin conjugate of synthetic phospho-Ser92 peptide
(CTRKIS-PO3-ASEFDR). The immune serum was purified over two sequen-
tial affinity columns, CTRKISASEFDR peptide immunosorbent and the
CTRKIS-PO3-ASEFDR peptide immunosorbent. Preparation of the recombi-
nant GST-PDE5 was as described (Liu et al., 2001).
Detection of in vitro–phosphorylated PDE5
200 ng of the purified nonphosphorylated and phosphorylated GST–PDE5
fusion proteins, respectively, were subjected to SDS-PAGE and transferred
to nitrocellulose. Membranes were incubated with the antiphospho-PDE5
antibody in a dilution of 1:10,000 followed by a peroxidase-coupled anti–
rabbit antibody (Sigma-Aldrich). Detection was performed using an ECL kit
(Amersham Pharmacia Biotech).
Detection of phosphorylated PDE5 in platelets
Platelet suspensions (4   10
8 platelets/ml) were stimulated with GSNO. At
the indicated time points, an aliquot (3.6   10
7 platelets) was removed
into Laemmli buffer and boiled for 10 min. Proteins were separated by
SDS-PAGE and transferred to nitrocellulose. Membranes were incubated
with phospho-PDE5–specific antibody in a dilution of 1:50,000. Detection
was performed as described above.
Materials
Sildenafil was a gift from Pfizer (Sandwich, UK). GSNO and monosucci-
nyl-tyrosyl-cGMP were obtained from Sigma-Aldrich. Anti-VASP antibody
was from Alexis Biochemicals Corp. Alkaline phosphatase was purchased
from Boehringer, EHNA was from Tocris Cookson. Activated charcoal was
from Riedel-de Haën. [ -
32P]GTP (800 Ci/mmol) was purchased from Du-
Pont, Na
125I was from Amersham Pharmacia Biotech. The bicinchoninic
acid protein determination kit was from Pierce Chemical Co. Chemicals
used for HPLC detection of GTP were of HPLC grade.
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